Acromegaly in 2000;L'acromegalie en l'an 2000

Annales d'Endocrinologie

Volumn 61, Issue 3, 2000, Pages 242-252

  Gervaise, N ^a   Combe, H ^a   Lecomte, P ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

Acromegaly; Cardiovascular mortality; Cure criteria; Sleep apnea syndrome; Somatostatin agonists; Surgery

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; SOMATOSTATIN;

ACROMEGALY; CARDIOVASCULAR DISEASE; COBALT THERAPY; HUMAN; HYPOPHYSECTOMY; RESPIRATORY TRACT DISEASE; REVIEW; ADENOMA; ADOLESCENT; ADULT; AGED; DRUG POTENTIATION; HYPOPHYSIS TUMOR; MIDDLE AGED; RADIOTHERAPY;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; MIDDLE AGED; PITUITARY NEOPLASMS; RADIOTHERAPY; RESPIRATORY TRACT DISEASES; SOMATOSTATIN;

EID: 0033813303     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term studies
2. Cabergoline in the treatment of acromegaly: A study of 64 patients
3. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience
4. Epidemiology of acromegaly in the Newcastle region
5. A case for hypothalamic acromegaly: A clinicopathological study of six patients with gangliocytomas producing growth hormone-releasing hormone
6. Acromegaly from ectopic growth hormone-releasing hormone secretion by a malignant carcinoid tumor: Successful treatment with long-acting somatostatin analog SMS 201-995
7. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor 1 in patients with acromegaly
8. Benign and malignant tumors in patients with acromegaly
9. An audit of outcome of treatment in acromegaly
10. Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion
11. Life expectancy following surgery for pituitary tumours
12. Radioimmunoassay of growth hormone-dependent insulin-like growth factor-binding protein in human plasma
13. Circulating levels and molecular distribution of the acid-labile subunit of the high molecular weight insulin-like growth factor-binding protein complex
14. The binding protein's binding protein-Clinical applications of Acid - Labile Subunit (ALS) measurement
15. Epidemiology and long-term survival in acromegaly
16. Acromegaly due to a growth hormone-releasing hormone-secreting bronchial carcinoid tumor: Further information on the abnormal responsiveness of the somatotrph cells and their recovery after successful treatment
17. Increased cerebrovascular mortality in patients with hypopituitarism
18. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide
19. Rapid improvement in sleep apnoea of acromegaly after short-term treatment with somatostatin analogue SMS 201-995
20. Decreased regional blood flow in patients with acromegaly
21. Serum IGF-1 and IGFBP-3 levels for the assessment of disease activity of acromegaly
22. Blood pressure-independent cardiac hypertrophy in acromegalic patients
23. New developments in the management of acromegaly. Should we achieve absolute biochemical cure?
24. Pituitary surgery for acromegaly should be done by specialists
25. Extensive personal experience: Acromegaly
26. Growth hormone and prolactin excess
27. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
28. Acromegaly with an adenomatous pharyngeal pituitary
29. A comparison between octreotide-LAR and lanreotide -SR in the chronic treatment of acromegaly
30. Long-term therapy with long-acting octreotide (Sandostatin LAR) for the management of acromegaly
31. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly
32. The prevalence of colonic polyps in acromegaly: A colonoscopic and pathological study in 103 patients
33. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated Growth Hormone-releasing hormone secreting carcinoid
34. Acromegaly: Clinical and biochemical features in 500 patients
35. Ectopic acromegaly
36. Insulin-like growth factor binding proteins: New proteins, new functions
37. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
38. Octreotide long-acting release: A review of its pharmaceutical properties and therapeutic use in the management of acromegaly
39. Criteria for cure of acromegaly: A consensus statement
40. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly
41. Sleep apnea in acromegaly
42. Central sleep apnea is associated with increased ventilatory response to carbon dioxide and hypersecretion of growth hormone in patients with acromegaly
43. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly
44. Sleep apnea in active acromegaly
45. Characterization of 24-hour growth hormone secretion in acromegaly: Implications for diagnosis and therapy
46. Obstructive sleep apnoea in acromegaly: The role of craniofacial changes
47. Serum acid-labile subunit in adult growth hormone deficiency and acromegaly
48. Low basal and persistent pulsatile growth hormone secretion are revealed in normal and hyposomatotropic men studied with a new ultrasensitive chemiluminescent assay
49. Collapsibility of passive pharynx in patients with acromegaly
50. Acromegaly: Recognition and treatment
51. Acromegaly and Cushing's syndrome due to ectopic production of GHRH and ACTH by a thymic carcinoid tumour: In vitro responses to GHRH and GHRP-6
52. L'acromegalie: Reflexions a propos du suivi de 104 patients
53. Les agonistes de la somatostatine dans le traitement de l'acromegalie
54. Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
55. Evolution of disease activity by IGF-1 and IGF binding protein-3 (IGFBP3) in acromegaly patients distributed according to a clinical score
56. The Birmingham pituitary database: Auditing the outcome of the treatment of acromegaly
57. Acromegaly, colonic polyps and carcinoma
58. Insulin-like growth factors, and their binding proteins: Biological actions
59. The ratio between levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1,2 and 3) decreases with age in healthy adults and is increased in acromegalic patients
60. Acid-labile subunit of human insulin-like growth factor binding protein complex: Measurement, molecular and clinical evaluation
61. Results of a European multicenter study with Sandostatin LAR in acromegalic patients
62. GTPase inhibiting mutations activate the chain of Gs and stimulate adenylyl cyclase in human pituitary tumors
63. Stereotactic radiosurgery for recurrent surgically treated acromegaly: Comparison with fractionated radiotherapy
64. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas
65. Urinary growth hormone excretion in acromegaly: Diagnostic value in mild disease activity
66. Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor
67. Acromegaly
68. Current treatment guidelines for acromegaly
69. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion
70. Gamma-knife surgery for secreting pituitary adenomas
71. Acromegaly
72. Octreotide as primary therapy for acromegaly
73. Usefulness of insulin-like growth factor binding protein-3 levels to determine acromegaly activity and effectiveness of transsphenoidal pituitary surgery
74. Mortality and cancer incidence in acromegaly: A retrospective cohort study
75. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy
76. Comparative study of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) level and IGF-I/IGFBP-3 ratio measurements and their relationship with an index of clinical activity in the management of patients with acromegaly
77. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1
78. Sleep apnoea and daytime sleepiness in acromegaly: Relationship to endocrinological factors
79. Sleep apnoea in acromegaly
80. Evaluation of acromegaly by measurement of 24-hourly urinary growth hormone excretion
81. Determinants of clinical outcome and survival in acromegaly
82. Acromegaly and gastrointestinal cancer
83. Sleep apnoea in treated acromegaly: Relative frequency and predisposing factors
84. Growth hormone and the heart
85. Sleep-disordered breathing in acromegalics. Relation of hormonal levels and quantitative sleep study by means of bedside oximeter
86. Acromegalie, expression clinique de la production de facteurs de liberation de l'hormone de croissance (GRF) par une tumeur pancreatique
87. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure
88. Acromegaly caused by pulmonary carcinoid tumors
89. A comparison of different methods for diagnosing acromegaly
90. Long-term mortality after transsphenoidal surgery, and adjunctive therapy for acromegaly
91. Somatotroph hyperplasia: Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor
92. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum Insuline-Like Growth Factor-1 but does not acutely stimulate serum GH
93. Treatment of acromegaly with the Growth Hormone-receptor antagonist Pegvisomant
94. Acromegaly: The significance of serum total and free IGF-1 and IGF-binding protein-3 in diagnosis
95. Reduction of the pituitary size by the somatostatin analog SMS 201-995 in a patient with an islet cell tumor secreting growth hormone-releasing factor
96. Mortality in acromegaly